RCUSArcus Biosciences, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-59.2% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$23M-1328.5% margin

Net Income

-$22M-1277.3% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$217M

Total Liabilities

$40M

Stockholders' Equity

$177M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-59.2%
Gross Profit	$2M	$4M	-59.2%
Operating Income	-$23M	-$12M	-91.4%
Net Income	-$22M	-$11M	-106.7%

RCUS Q3 2019 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena